Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Gains from Sales and Divestitures data on record, last reported at $21318.0 in Q1 2026.

  • On a quarterly basis, Gains from Sales and Divestitures rose 93.75% to $21318.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $21318.0, a 93.75% increase, with the full-year FY2025 number at $19505.0, down 12.64% from a year prior.
  • Gains from Sales and Divestitures reached $21318.0 in Q1 2026 per FULC's latest filing, up from $19505.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for FULC hit a ceiling of $22326.0 in Q2 2024 and a floor of $5496.0 in Q1 2023.
  • A 5-year average of $16212.1 and a median of $18144.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 76.26% in 2022, then surged 110.15% in 2024.
  • Tracing FULC's Gains from Sales and Divestitures over 5 years: stood at $10174.0 in 2022, then soared by 78.34% to $18144.0 in 2023, then increased by 23.05% to $22326.0 in 2024, then decreased by 12.64% to $19505.0 in 2025, then grew by 9.3% to $21318.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for FULC at $21318.0 in Q1 2026, $19505.0 in Q4 2025, and $19505.0 in Q3 2025.